Clinical data | |
---|---|
Trade names | Thioderon |
Other names | 10364-S; Epitiostanol 17β-(1-methoxy)cyclopentyl ether; 17β-[(1-Methoxycyclopentyl)oxy]-2α,3α-epithio-5α-androstane |
AHFS/Drugs.com | International Drug Names |
Routes of administration | By mouth |
Drug class | Androgen; Anabolic steroid; Androgen ether; Antiestrogen |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C25H40O2S |
Molar mass | 404.65 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Mepitiostane, sold under the brand name Thioderon, is an orally active antiestrogen and anabolic–androgenic steroid (AAS) of the dihydrotestosterone (DHT) group which is marketed in Japan as an antineoplastic agent for the treatment of breast cancer.[1][2][3][4][5] It is a prodrug of epitiostanol.[6][7] The drug was patented and described in 1968.[1]
Stella_2007
was invoked but never defined (see the help page).